Our pipeline
We have an exciting and balanced pipeline underpinned by great science.
Home / Our therapy areas / Our pipeline
Latest quarterly updates
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
194
projects in our pipeline
18
new molecular entities in our late-stage pipeline
1
new molecular entity approved
Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).
Oncology (as of 29 April 2025)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Cardiovascular, Renal and Metabolism (as of 29 April 2025)
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
Respiratory & Immunology (as of 29 April 2025)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Rare Disease (as of 29 April 2025)
Phase I
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Vaccine & Immune therapies (as of 29 April 2025)
Phase I
Phase I
Phase II
Phase III
LCM Projects